Used in research and development of cancer therapies, particularly for tumors that overexpress the insulin-like growth factor 1 receptor (IGF-1R), such as breast, colorectal, and lung cancers. This reference antibody (cixutumumab) inhibits the binding of IGF-1 and IGF-2 to IGF-1R, reducing cancer cell proliferation and tumor metastasis. It serves as a reference standard in immunoassays and binding studies to evaluate the performance of other anti-IGF1R antibodies. Supports the characterization of therapeutic antibody candidates by providing a benchmark for affinity, specificity, and epitope binding. Employed in pharmacokinetic and pharmacodynamic studies during preclinical and clinical development. Also utilized in flow cytometry, immunohistochemistry, and Western blotting to detect IGF-1R expression in cell lines and tissue samples. Additionally, facilitates the study of IGF-1R signaling pathways in biological systems.